RGCC International

16/02/2026

Shining the spotlight on our sister company, Welmedis!

Aiming to transform cancer therapy by developing targeted therapeutics, Welmedis is dedicated to developing novel medications that target the unique characteristics of each patient’s cancer, offering more effective and tailored therapeutic solutions.

Using gene and protein expression data from the target identification pipeline, Welmedis identifies novel targets for small-molecule therapeutics tailored to specific patient populations. Their innovative approach combines cutting-edge diagnostics and drug development to provide the most effective treatments for specific cancer types.

Learn more about Welmedis >

We deliver personalized cancer treatments powered by diagnostic insights. Discover more about our mission and our cutting-edge work.

12/02/2026

The information gained from Immune-Frame enables healthcare professionals to identify potential immune dysregulations or health risks, guide treatment strategy, and track immune recovery following therapies such as chemotherapy, immunotherapy, or cellular therapy.

👉 Understand your immune system’s health and performance: rgcc-international.com/tests/immune-frame/

09/02/2026

RGCC tests offer valuable insights into the most effective treatment options for each patient.

Our panels evaluate how different anti-cancer drugs and natural substances target cells uniquely in each individual. Plus, they also include genetic detailing on the cancer cells to let you know how gene expressions and physiological expressions manifest in a cancer patient’s body.

🔗 Learn more >> rgcc-international.com/tests

04/02/2026

February 4 marks World Cancer Day, a global initiative dedicated to raising awareness and driving action against .

It is an important opportunity to highlight key risk factors and the preventive actions that can help reduce cancer risk, such as limiting to***co use and alcohol consumption, reducing exposure to ultraviolet radiation from the sun, and adopting healthier lifestyle choices.

Today, we stand with the global community to promote prevention, raise awareness, and support efforts toward a healthier future for all.

🎗 Join the global movement for World Cancer Day and learn more: worldcancerday.org

26/01/2026

Dr. Clayton Bell, Functional & Integrative Medicine Physician, shares how he incorporates RGCC testing into his clinical decision-making to help guide personalized treatment approaches.

By using the Onconomics panels, Dr. Bell gains insights that support treatment planning, helping physicians evaluate potential responsiveness to chemotherapy agents, immunotherapies, and hormone-blocking therapies for each individual patient.

Watch the full interview:
📽️ youtube.com/watch?v=98GK0V5OI3U&t=7s

22/01/2026

🌍 Cervical remains a global health challenge, with approximately 660,000 new cases diagnosed worldwide each year, the majority occurring in middle- and low-income regions. These disparities largely reflect unequal access to vaccination (one of the main risk factors for cervical cancer), cervical screening, timely treatment, and broader social and economic determinants of health.

Expanding access to prevention and early detection has the potential to significantly reduce incidence and save lives.

🔗 Learn more about and treatment options: https://rgcc-international.com/patient-information/cervical-cancer-treatment/

19/01/2026

Circulating Tumor Cells (CTCs) are a key indicator of active in the body. Monitoring the CTC levels helps clinicians assess disease progression and evaluate treatment response.
A high CTC count may indicate an increased risk of recurrence, making regular CTC testing an essential part of managing cancer treatment.

👉 Learn more about tests >> https://rgcc-international.com/research-and-development/

15/01/2026

The Oncotrail RGCC test provides crucial information on the presence of circulating tumor cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific types of .

The Oncotrail RGCC test analyzes the markers for very specific types of cancer, including:

✔️ Breast cancer
✔️ Colon cancer
✔️ GI cancer
✔️ Melanoma cancer
✔️ Lung cancer
✔️ Sarcoma cancer
✔️ Prostate cancer

Learn more about the test here: rgcc-international.com/tests/oncotrail-rgcc/

13/01/2026

We are proud to share that, as part of our ongoing commitment to Corporate Social Responsibility, RGCC International has donated €15,000 to the Department of Pediatric Oncology and Hematology at Charité - University Medicine Berlin.

Funds from this donation will support Charité - Universitätsmedizin Berlin's pioneering research program, helping advance innovative immunotherapies for children battling cancer.

We remain committed to our CSR mission and will continue to support organizations and research programs that promote health, innovation, and well-being worldwide. To read the full press release, visit:

As part of its CSR activities, RGCC Donates €15,000 to Support CAR-T Cell Therapy Research at Charité – Universitätsmedizin Berlin

08/01/2026

Liquid biopsies are helping transform how treatment decisions are informed in care.

Dr. Clifford Fetters, MD, shares how testing supports physicians by providing insights from circulating tumor cells, helping guide decisions across chemotherapy, natural, and supportive approaches, tailored to the individual patient.

👉 Learn more about our testing approaches: rgcc-international.com/tests/

24/12/2025

As 2025 comes to a close, we extend our heartfelt gratitude to our partners, clinicians, and patients around the world.
May your holidays be filled with peace, health, and hope for the year ahead.
✨ Happy holidays from all of us at RGCC.

18/12/2025

🎉 Reflecting on a remarkable 2025 at RGCC!

As 2025 draws to a close, we take a moment to reflect on a year marked by scientific progress, collaboration, and continued commitment to advancing personalized oncology.

This year, strengthened its global presence through international gatherings, scientific conferences, and collaborative research initiatives that united leading oncologists, healthcare practitioners, and researchers from around the world. We also celebrated important milestones, including the launch of the InVyomma Plus test.

As we look ahead to 2026, we remain dedicated to expanding the frontiers of precision medicine and supporting clinicians in providing truly personalized cancer care.